The primary analysis compared time to all-cause death among patients with AML based on FLT3 and NPM1 mutation status, age (<65 years, ≥65 years), and cytogenetic risk group (unfavorable, intermediate/normal, favorable). The gene discussed is FLT3; the disease is acute myeloid leukemia.